Dr Reddys Wins Brazil Generic Ozempic Approval
Indian drugmaker Dr Reddys Laboratories has secured Brazilian regulatory approval to market a generic version of Novo Nordisks diabetes drug Ozempic. The treatment will be available in specific doses for adults with type 2 diabetes.
Xurve View
Insights:
Xurve View
Dr. Reddy's Laboratories secured Brazilian regulatory approval on Thursday morning to market a generic version of Novo Nordisk's diabetes drug Ozempic. The authorization opens access in a market with 16.6 million adults living with diabetes. The approval provides the Indian pharmaceutical firm a major foothold in Latin America's largest healthcare market.
